Pathogenesis and laboratory diagnosis of hereditary angioedema

Allergy and Asthma Proceedings

Volumn 30, Issue 5, 2009, Pages 487-492

  Zuraw, Bruce L ^a   Christiansen, Sandra C ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

Angioedema; Bradykinin; C1 inhibitor; C2 kinin; Complement; Contact system; HAE; Hageman factor; High molecular weight kininogen; Mutation; Plasma kallikrein

Indexed keywords

BLOOD CLOTTING FACTOR 11A; BLOOD CLOTTING FACTOR 12; BLOOD CLOTTING FACTOR 12A; BLOOD CLOTTING FACTOR 12F; BRADYKININ; COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C1S INHIBITOR; COMPLEMENT COMPONENT C2; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HIGH MOLECULAR WEIGHT KININOGEN; PLASMA KALLIKREIN; PROTEINASE INHIBITOR; UNCLASSIFIED DRUG;

ADULT; ANGIONEUROTIC EDEMA; CASE REPORT; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; DISEASE CLASSIFICATION; GENE MUTATION; HUMAN; IMMUNOBLOTTING; LABORATORY DIAGNOSIS; MOLECULAR BIOLOGY; PATHOGENESIS; PATHOPHYSIOLOGY;

ANGIOEDEMAS, HEREDITARY; BRADYKININ; CAPILLARY PERMEABILITY; COMPLEMENT C1 INACTIVATOR PROTEINS; COMPLEMENT C1R; COMPLEMENT C1S; COMPLEMENT C2; FACTOR XII; HUMANS; MANNOSE-BINDING PROTEIN-ASSOCIATED SERINE PROTEASES; PLASMA KALLIKREIN;

EID: 73249128396     PISSN: 10885412     EISSN: 15396304     Source Type: Journal    
DOI: 10.2500/aap.2009.30.3277     Document Type: Conference Paper

References (61)

1. Osler W. Hereditary angio-neurotic oedema. Am J Med Sci 95:362-367, 1888.
2. Zuraw BL. Clinical practice. Hereditary angioedema. N Engl J Med 359:1027-1036, 2008.
3. Frank MM, Gelfand JA, and Atkinson JP. Hereditary angioedema: The clinical syndrome and its management. Ann Intern Med 84:586-593, 1976.
4. Farkas H, Varga L, Szeplaki G, et al. Management of hereditary angioedema in pediatric patients. Pediatrics 120:e713-e722, 2007.
5. Agostoni A, and Cicardi M. Hereditary and acquired C1-inhibitor deficiency: Biological and clinical characteristics in 235 patients. Medicine (Baltimore) 71:206-215, 1992.
6. Molina C, Brun J, Coulet M, et al. Diagnostic and therapeutic problems associated with hereditary deficiency of the C1 esterase inhibitor. Clin Allergy 7:127-135, 1977.
7. Landerman NS, Webster ME, Becker EL, and Ratcliffe HE. Hereditary angioneurotic edema. II. Deficiency of inhibitor for serum globulin permeability factor and/or plasma kallikrein. J Allergy 33:330-341, 1962.
8. Donaldson VH, and Evans RR. A biochemical abnormality in hereditary angioneurotic edema: Absence of serum inhibitor of C′1-esterase. Am J Med 35:37-44, 1963.
9. Davis AE III. C1 inhibitor and hereditary angioneurotic edema. Annu Rev Immunol 6:595-628, 1988.
10. Lomas DA, Belorgey D, Mallya M, et al. Molecular mousetraps and the serpinopathies. Biochem Soc Trans 33:321-330, 2005.
11. Zuraw BL, and Curd JG. Demonstration of modified inactive first component of complement (C1) inhibitor in the plasmas of C1 inhibitor-deficient patients. J Clin Invest 78:567-575, 1986.
12. Bock SC, Skriver K, Nielsen E, et al. Human C1 inhibitor: Primary structure, cDNA cloning, and chromosomal localization. Biochemistry 25:4292-4301, 1986.
13. Carter PE, Duponchel C, Tosi M, and Fothergill JE. Complete nucleotide sequence of the gene for human C1 inhibitor with an unusually high density of Alu elements. Eur J Biochem 197:301-308, 1991.
14. Beinrohr L, Harmat V, Dobo J, et al. C1 inhibitor serpin domain structure reveals the likely mechanism of heparin potentiation and conformational disease. J Biol Chem 282:21100-21109, 2007.
15. Bissler JJ, Aulak KS, Donaldson VH, et al. Molecular defects in hereditary angioneurotic edema. Proc Assoc Am Physicians 109:164-173, 1997.
16. Verpy E, Biasotto M, Brai M, et al. Exhaustive mutation scanning by fluorescence-assisted mismatch analysis discloses new genotype-phenotype correlations in angiodema. Am J Hum Genet 59:308-319, 1996.
17. Zuraw BL, and Herschbach J. Detection of C1 inhibitor mutations in patients with hereditary angioedema. J Allergy Clin Immunol 105:541-546, 2000.
18. Gosswein T, Kocot A, Emmert G, et al. Mutational spectrum of the C1INH (SERPING1) gene in patients with hereditary angioedema. Cytogenet Genome Res 121:181-188, 2008.
19. Kalmár L, Hegedûs T, and Tordai A. HAEdb C1 inhibitor gene mutation database. Available online at hae.enzim.hu/; last accessed August 2009.
20. Pappalardo E, Cicardi M, Duponchel C, et al. Frequent de novo mutations and exon deletions in the C1inhibitor gene of patients with angioedema. J Allergy Clin Immunol 106:1147-1154, 2000.
21. Donaldson VH, Ratnoff OD, Da Silva WD, and Rosen FS. Permeability- increasing activity in hereditary angioneurotic edema plasma. II. Mechanism of formation and partial characterization. J Clin Invest 48:642-653, 1969.
22. Donaldson VH, Rosen FS, and Bing DH. Role of the second component of complement (C2) and plasmin in kinin release in hereditary angioneurotic edema (H.A.N.E.) plasma. Trans Assoc Am Physicians 40:174-183, 1977.
23. Curd JG, Prograis L Jr, and Cochrane CG. Detection of active kallikein in induced blister fluids of hereditary angioedema patients. J Exp Med 152:742-747, 1980.
24. Austen KF, and Sheffer AL. Detection of hereditary angioneurotic edema by demonstration of a profound reduction in the second component of human complement. N Engl J Med 272: 649-656, 1965.
25. Carpenter CB, Ruddy S, Shehadeh IH, et al. Complement metabolism in man: Hypercatabolism of the fourth (C4) and third (C3) components in patients with renal allograft rejection and hereditary angioedema (HAE). J Clin Invest 48:1495-1505, 1969.
26. Laurell AB, Martensson U, and Sjoholm AG. C1 subcomponent complexes in normal and pathological sera studied by crossed immunoelectrophoresis. Acta Pathol Microbiol Scand C 84C: 455-464, 1976.
27. Klemperer MR, Donaldson VH, and Rosen FS. Effect of C′1 esterase on vascular permeability in man: Studies in normal and complement-deficient individuals and in patients with hereditary angioneurotic edema. J Clin Invest 47:604-611, 1968.
28. Strang CJ, Cholin S, Spragg J, et al. Angioedema induced by a peptide derived from complement component C2. J Exp Med 168:1685-1698, 1988.
29. Curd JG, Yelvington M, Burridge N, et al. Generation of bradykinin during incubation of hereditary angioedema plasma. Mol Immunol 19:1365, 1983.
30. Fields T, Ghebrehiwet B, and Kaplan AP. Kinin formation in hereditary angioedema plasma: Evidence against kinin derivation from C2 and in support of "spontaneous" formation of bradykinin. J Allergy Clin Immunol 72:54-60, 1983.
31. Lammle B, Zuraw BL, Heeb MJ, et al. Detection and quantitation of cleaved and uncleaved high molecular weight kininogen in plasma by ligand blotting with radiolabeled plasma prekallikrein or factor XI. Thromb Haemost 59:151-161, 1988.
32. Berrettini M, Lammle B, White T, et al. Detection of in vitro and in vivo cleavage of high molecular weight kininogen in human plasma by immunoblotting with monoclonal antibodies. Blood 68:455-462, 1986.
33. Schapira M, Silver LD, Scott CF, et al. Prekallikrein activation and high-molecular-weight kininogen consumption in hereditary angioedema. N Engl J Med 308:1050-1054, 1983.
34. Nussberger J, Cugno M, Amstutz C, et al. Plasma bradykinin in angio-oedema. Lancet 351:1693-1697, 1998.
35. Zuraw BL, Lammle B, Sugimoto S, et al. Cleavage of high molecular weight kininogen in plasma during attacks of angioedema in hereditary angioedema. J Allergy Clin Immunol 79:177, 1987.
36. Shoemaker LR, Schurman SJ, Donaldson VH, and Davis AE. Hereditary angioneurotic oedema: Characterization of plasma kinin and vascular permeability-enhancing activities. Clin Exp Immunol 95:22-28, 1994.
37. Han ED, MacFarlane RC, Mulligan AN, et al. Increased vascular permeability in C1 inhibitor-deficient mice mediated by the bradykinin type 2 receptor. J Clin Invest 109:1057-1063, 2002.
38. Zuraw BL, and Christiansen SC. New promise and hope for treating hereditary angioedema. Expert Opin Investig Drugs 17:697-706, 2008.
39. Bork K, Frank J, Grundt B, et al. Treatment of acute edema attacks in hereditary angioedema with a bradykinin receptor-2 antagonist (Icatibant). J Allergy Clin Immunol 119:1497-1503, 2007.
40. Byrd JB, Adam A, and Brown NJ. Angiotensin-converting enzyme inhibitor-associated angioedema. Immunol Allergy Clin North Am 26:725-737, 2006.
41. Shepherd GM. Possible contraindication of angiotensin converting enzyme inhibitors in patients with hereditary angioedema. Am J Med 88:446, 1990.
42. Frank MM. Effect of sex hormones on the complement-related clinical disorder of hereditary angioedema. Arthritis Rheum 22:1295-1299, 1979.
43. Bouillet L, Longhurst H, Boccon-Gibod I, et al. Disease expression in women with hereditary angioedema. Am J Obstet Gynecol 119:484 e1-4, 2008.
44. Chappatte O, and De Swiet M. Hereditary angioneurotic oedema and pregnancy. Case reports and review of the literature. Br J Obstet Gynaecol 95:938-942, 1988.
45. Farsetti A, Misiti S, Citarella F, et al. Molecular basis of estrogen regulation of Hageman factor XII gene expression. Endocrinology 136:5076-5083, 1995.
46. Citarella F, Misiti S, Felici A, et al. Estrogen induction and contact phase activation of human factor XII. Steroids 61:270-276, 1996.
47. Verpy E, Couture-Tosi E, Eldering E, et al. Crucial residues in the carboxy-terminal end of C1 inhibitor revealed by pathogenic mutants impaired in secretion or function. J Clin Invest 95:350-359, 1995.
48. Rosen FS, Charache P, Pensky J, and Donaldson VH. Hereditary angioneurotic edema: Two genetic variants. Science 148:957-958, 1965.
49. Rosen FS, Alper CA, Pensky J, et al. Genetically determined heterogeneity of the C1 esterase inhibitor in patients with hereditary angioneurotic edema. J Clin Invest 50:2143-2149, 1971.
50. Wagenaar-Bos IG, and Hack CE. Structure and function of C1-inhibitor. Immunol Allergy Clin North Am 26:615-632, 2006.
51. Bork K, Barnstedt SE, Koch P, and Traupe H. Hereditary angioedema with normal C1-inhibitor activity in women. Lancet 356:213-217, 2000.
52. Binkley KE, and Davis A III. Clinical, biochemical, and genetic characterization of a novel estrogen-dependent inherited form of angioedema. J Allergy Clin Immunol 106:546-550, 2000
53. Bork K, Gul D, Hardt J, and Dewald G. Hereditary angioedema with normal C1 inhibitor: Clinical symptoms and course. Am J Med 120:987-992, 2007.
54. Bork K. Hereditary angioedema with normal C1 inhibitor activity including hereditary angioedema with coagulation factor XII gene mutations. Immunol Allergy Clin North Am 26:709-724, 2006.
55. Cichon S, Martin L, Hennies HC, et al. Increased activity of coagulation factor XII (Hageman factor) causes hereditary angioedema type III. Am J Hum Genet 79:1098-1104, 2006.
56. Dewald G, and Bork K. Missense mutations in the coagulation factor XII (Hageman factor) gene in hereditary angioedema with normal C1 inhibitor. Biochem Biophys Res Commun 343: 1286-1289, 2006.
57. Duan QL, Binkley K, and Rouleau GA. Genetic analysis of factor XII and bradykinin catabolic enzymes in a family with estrogen-dependent inherited angioedema. J Allergy Clin Immunol 123:906-910, 2009.
58. Bowen T, Cicardi M, Bork K, et al. Hereditary angiodema: A current state-of-the-art review, VII: Canadian Hungarian 2007 International Consensus Algorithm for the Diagnosis, Therapy, and Management of Hereditary Angioedema. Ann Allergy Asthma Immunol 100:S30-S40, 2008.
59. Gompels MM, Lock RJ, Abinun M, et al. C1 inhibitor deficiency: Consensus document. Clin Exp Immunol 139:379-394, 2005.
60. Zuraw BL, Sugimoto S, and Curd JG. The value of rocket immunoelectrophoresis for C4 activation in the evaluation of patients with angioedema or C1-inhibitor deficiency. J Allergy Clin Immunol 78:1115-1120, 1986.
61. Gompels MM, Lock RJ, Morgan JE, et al. A multicentre evaluation of the diagnostic efficiency of serological investigations for C1 inhibitor deficiency. J Clin Pathol 55:145-147, 2002.